In a capital-constrained environment, Enveda distinguished itself by securing high-quality funding at a rapid clip—closing a $150M Series D in late 2025 to achieve "unicorn" status just five years after its seed round. In this fireside chat, UBS Senior Biotechnology Analyst Mike Yee sits down with CEO Viswa Colluru, PhD, to unpack the strategy behind Enveda’s outlier success. They will discuss how Enveda validated its platform to investors by moving faster than the industry average (from concept to clinic), how they secured backing from giants like Premji Invest and Sanofi, and how they are generating tangible value by using AI to analyze natural samples to advise candidate selection and enable three drugs in different indications to already reach clinical trials.